A carregar...
97. Competition Experiments for the Baloxavir-Resistant I38T Influenza A Mutant
BACKGROUND: Baloxavir marboxil (BXM), a cap-dependent endonuclease inhibitor, has been recently approved in the United States for the treatment of influenza infections. It is superior to oseltamivir for reducing the time of viral shedding but is reported to have a low barrier of resistance. We sough...
Na minha lista:
| Publicado no: | Open Forum Infect Dis |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Oxford University Press
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6808909/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofz359.021 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|